| Title |
Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, June 2017
|
| DOI | 10.1007/s10549-017-4348-8 |
| Pubmed ID | |
| Authors |
Xi Tan, Tareq Fabian Camacho, Virginia T. LeBaron, Leslie J. Blackhall, Rajesh Balkrishnan |
| Abstract |
To explore differences in opioid use across different adjuvant endocrine therapy (AET) regimens, factors associated with opioid use, and the impact of opioid use on overall survival in female breast cancer patients treated with AET. This retrospective study analyzed 2006-2012 SEER-Medicare datasets, following patients for at least two years from the index date, defined as the first date they filled an AET prescription. The study included adult women with incident, primary, hormone-receptor-positive, stage I-III breast cancer. They were also first-time AET users, and fee-for-service Medicare enrollees continuously enrolled in Medicare Parts A, B, and D. The main independent variable was the AET regimen. We measured whether patients used opioids after the initiation of AET. After the adjustment of inverse probability treatment weights and unbalanced covariates, the average treatment effect probabilities of opioid use were similar between those who used aromatase inhibitors (AI) only and those used tamoxifen (TAM) only (56.2 vs. 55.3%, respectively). Opioid use probabilities for those who switched from AI to TAM were higher than those for the TAM-only and AI-only groups. Opioid use was also significantly associated with AET non-adherence. Opioid users had a significantly higher risk of death (adjusted hazard ratio [HR] = 1.59, p < 0.001). Switching from AI to TAM was associated with a high likelihood of opioid use. Opioid use was significantly associated with AET non-adherence and higher risk of mortality in female Medicare beneficiaries with breast cancer even after adjusting for adherence. |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 19% |
| Other | 4 | 11% |
| Student > Doctoral Student | 2 | 5% |
| Student > Bachelor | 2 | 5% |
| Researcher | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 17 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Business, Management and Accounting | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Sports and Recreations | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 19 | 51% |
Attention Score in Context
This research output has an Altmetric Attention Score of 622. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2018.
All research outputs
#29,448
of 22,999,744 outputs
Outputs from Breast Cancer Research and Treatment
#2
of 4,677 outputs
Outputs of similar age
#668
of 316,827 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#1
of 93 outputs
Altmetric has tracked 22,999,744 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,677 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,827 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.